Pulmonary neoplastic thrombotic microangiopathy (PTTM)
Conditions
Interventions
PTTM group:Anrotinib 12mg QD treatment
Sponsors
The First Affiliated Hospital of Soochow University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age =18 years; 2. Histologically or cytologically confirmed solid malignant tumor; 3. ECOG performance status score of 0–4; 4. No prior treatment with VEGF/VEGFR inhibitors (including but not limited to sunitinib, bevacizumab, anlotinib, apatinib, or endostar); 5. Meeting the clinical diagnostic criteria for pulmonary tumor thrombotic microangiopathy (PTTM).
Exclusion criteria
Exclusion criteria: 1. Receipt of any investigational drug therapy or participation in an interventional clinical trial within 28 days prior to the first dose; 2. Known history of hypersensitivity to anlotinib (including its active/inactive excipients) or other drugs with similar structures or pharmacological classes; 3. Concurrent severe infections, including but not limited to drug-resistant bacterial infections, bloodstream infections, opportunistic infections, or refractory infections as assessed by the investigator; 4. Presence of septic shock.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Oxygenation index improved by 50% from baseline after 1 week of anrotinib treatment;50% improvement in D-dimer kinetics after 1 week of treatment with amlotinib;Tricuspid Transvalvular Pressure Reduced by 30% from Baseline After 1 Week of Anrotinib Treatment; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;OS;DOR;Adverse event rate;Serious adverse event rate;Incidence of adverse events or serious adverse events leading to treatment discontinuation; | — |
Countries
China
Contacts
Public ContactCheng Chen
The First Affiliated Hospital of Soochow University
Outcome results
None listed